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Tigecycline shows great antimicrobial activity against both Gram-positive and Gram-negative bacteria, and has been
considered to be an appropriate choice in controlling infection caused by multi-drug resistant (MDR) pathogens,
such as carbapenemase-producing Enterobacteriaceae (CPE). Although many clinical trials evaluate the efficacy and
safety of tigecycline on adults, rare reports recommend tigecycline to treat pediatric patient. In this study, we
presented a clinical case with tigecycline as an anti-infectious agent on a 14-year-old child who was suffering from
infection of intraperitoneal abscess caused by Klebsiella pneumoniae carbapenemases (KPC)-producing Escherichia
coli with extreme drug resistant profile. By accessing the clinical outcome and efficacy of the patient, and the side
effects of tigecycline, our research explored the documented experience of tigecycline on controlling infection
caused by CPE isolate in children.
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Carbapenems have been considered to be the last-line
antimicrobial agents to against multiple drug resistant
(MDR) Gram-negative bacteria for a long time. While
recently, the emergence of carbapenemase-producing
Enterobacteriaceae (CPE) has been reported worldwide
increasingly, which has raised global concern for those
isolates shows hydrolytic activities to multiple antibi-
otics including carbapenems [1-3]. There are many
carbapenemases involved in CPE isolates, in which
Klebsiella pneumoniae carbapenemases (KPCs) plays a
vital role [1-3]. Although the susceptibility data in vitro
indicate that colistin, tigecycline, and fosfomycin are
effective to CPE isolates, the optimal treatment choice
hasn’t reached agreement yet [2]. Among the above three
selectable agents, tigecycline, a semi-synthetic derivative
of minocycline and a member of the tetracycline family,
shows superiority due to a wider anti-bacterial spectrum
especially to MDR pathogens and better tissue permeabil-
ity particularly to complicated intra-abdominal infection
(cIAI) [4,5]. In practice, tigecycline has been approved to* Correspondence: yvys119@163.com
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reproduction in any medium, provided the ortreat infection caused by MDR Gram-negative pathogen,
especially for the care of critically ill patients [6]. How-
ever, it is still not been recommended to be used in
pediatric patients, not mention to treat infection caused
by blaKPC-positive isolates. We reported here a docu-
mented case about a 14-year-old child who was infected
by KPC-producing Escherichia coli and was treated with
tigecycline.Case report
On September 13, 2012, a 14-year-old Chinese patient was
transferred to our hospital (Sir Run Run Shaw Hospital,
Hangzhou, Zhejiang province, China) due to postoperative
intraperitoneal abscess infection of appendicitis.
Three weeks ago (August 25, 2012), the patient was
admitted to a local hospital of Hangzhou for vague
abdominal pain of the right lower quadrant for one day.
The pain was aggravated while walking, but was relieved
when lying with knees bent. Total leukocyte count was
11.5 × 109/L with 63.7% neutrophils, his hemoglobin was
13.2 g/dL, and platelet count was 229 × 109/L. The clin-
ical diagnosis of acute appendicitis was confirmed by the
B-ultrasonography. Then appendectomy was conducted
immediately. While just after the operation, the patientThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and fever (over 39°C). The complete blood count (CBC)
results indicated that the leukocyte count increased to
14.3 × 109/L with 91.5% neutrophils, and C-reactive pro-
tein (CRP) level arrived to 523 mg/L. The patient received
aztreonam (1 g q12h) and etimicin sulfate (0.2 g qd) to
control postoperative infection for two days, while he
persisted with high fever and further developed to
lower back pain, accompanied with nausea, vomiting
(two to three times per day) and diarrhea (six to seven
times per day). Considering the anti-infective effect
unsatisfied, moxalactam (latamoxef, 1 g q12h) was pre-
scribed to the patient on the forth hospital day. At this
time, computed tomography (CT) scan was conducted,
which indicated seroperitoneum, pneumatosis, swelling
of soft tissue near right psoas, right kidney enlarge-
ment and pleural effusion. Leukocyte count was still
high as 12.3 × 109/L with 78.3% neutrophils, and CRP
was 96.1 mg/L. Antibiotic treatment was then switched
to imipenem (0.5 g q8h) on the fifth hospital day. The
temperature could be controlled within 37.5°C to 38°C
during the usage of imipenem. Two weeks later, the patient
deteriorated to incision suppurates and was transferred to
our hospital for further treatment.
Physical examination showed that abdomen was soft
and flat, tenderness and rebound tenderness were positive
around the incision site. A 3cm-long incision in the right
lower quadrant was swelling and purulent. Percussion pain
of the right renal region was positive. The leukocyte count
was 10.0 × 109/L with 6.5% neutrophils, 70.7% lymphocytes,
and 21% monocytes. The hemoglobin, platelets, CRP and
procalcitonin (PCT) were 10.7 g/dL, 117 × 109/L, 116.7 mg/L
and 2.3 ng/ml, respectively. CT scan showed abscesses
spread to right paracolic sulcus, iliaca fossa and liver. On
September 14 (the second hospital day in our hospital), the
patient’s condition was suddenly worsened, with blood
pressure and SaO2 down to 70/40 mmHg and 90%, heart
rate and respiratory rate up to 130 beats and 25 per minute,
which suggested sepsis shock happened. The patient
received the second abdominal surgery immediately to re-
pair intestinal fistula. Two E. coli isolates were isolated from
continual abdominal effusion culture, both of which were
pan-resistant to antimicrobial agents by VITEK 2 system,
but susceptible to tigecycline, colistin and fosfomycin with
MIC 0.25 mg/L, 0.5 mg/L and 16 mg/L using E-test method,
respectively (Table 1). According to the susceptibility result,
it seemed that only three antibiotics could be used in thisTable 1 The susceptibility results
Isolates TZP AMK CRO FEP GEN
E. coli (isolate 1 and 2) ≥128 ≥64 ≥64 64 ≥16
E. colace (isolate 3) ≤4 2 ≤1 ≤1 ≤1
Note: TZP, piperacillin/tazobactam; AMK, amikacin; CRO, ceftriaxone; FEP, cefepime;
imipenem; MEM, meropenem; TGC, tigecycline; CST, colistin; FOM, fosfomycin.case, while colistin is unavailable in China mainland
nowadays. It is highly recommended that fosfomycin
be used in combination with other agents for the treatment
of infections with CPE to prevent the emergence of resist-
ance to this agent [7], so the combination of tigecycline
(first dose of 100 mg, then 50 mg q12h, according to
1 mg/kg body weight) and intravenous fosfomycin
(4 g q12h) was given to the patient. But fosfomycin had
to be stopped in the next day due to its adverse reaction
(serious vomiting). Six days after the usage of tigecycline,
a Enterobacter cloacae isolate resistant to tigecycline with
MIC 4 mg/L but susceptible to most β-lactam antibiotics
was separated (Table 1), then the antibiotic treatment
was switched to cefepime (2 g q12h). Leukocyte count
decreased to 8.1 × 109/L with 34.1% neutrophils, 39%
lymphocytes, and 26.5% monocytes, and CRP to 9 mg/L.
On the 13th hospitalization day in our hospital, the patient
was improved greatly and then discharged.
Genes associated with carbapenems resistance were
detected on the above two E. coli isolates, as previous
reported, which showed both of them carried blaKPC-2
and blaCTX-M-24 gene [8,9].
Discussion
KPC-producing Enterobacteriaceae, as one of MDR patho-
gens associated to healthcare-associated infection (HCAI)
with high mortality, has raised global concern for the
outbreaks in northeast of USA, Israel and the east China
in recent years [1]. Enterobacteriaceae isolates carrying
KPCs enzyme exhibit hydrolyzing-activity to wide spectrum
of β-lactams, including penicillins, cephalosporins,
aztreonam, and even carbapenems. Seriously, most of them
usually co-harbor other resistant genes mediating resistance
to multiple classes of antibiotics such as fluoroquinolones
or aminoglycosides [3], which leads to MDR events. When
CPE isolates evolve to MDR, clinical therapy would be
immersed to serious situation. The combination of different
antibiotics with synergistic mechanisms of action not only
may be useful for the management of multidrug-resistant
Gram-negative infections but also can lessen the chance of
resistance development.
Reports have given some suggestions on combination
schemes to CPE isolates [10]. Based on the synergic effect
between third generation cephalosporins and amoxicillin/
clavulanic acid to KPC producers in vitro, some experts
consider cephalosposins like cefepime in combination with
amoxicillin/clavulanic acid could produce well effect, but itCPS ETP IPM MEM TGC CST FOM
96 ≥8 ≥16 8 0.25 0.5 16
0.19 ≤0.5 2 0.064 4 24 8
GEN, gentamicin; CPS, cefoperazone/sulbactam; ETP, ertapenem; IPM,
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tigecycline and fosfomycin also show pretty well sus-
ceptibility to CPE in vitro. Combination therapy based
on tigecycline or colistin is considered to be one of
the other appropriate choice [12,13]. To those isolates
with lower carbapenems MICs, combination based on
carbapenems would also be effective. In our case, owning
to the very slight synergic effect of cefepime in combination
with amoxilin/ clavulanic acid observed in vitro, colistin
being unavailable in China mainland and high level of
carbapenems MICs (IMP ≥ 16), tigecycline combined with
fosfomycin seems to be our unique treatment option.
The activity of tigecycline in vitro has been recog-
nized, and in vivo both the efficiency and the security
of tigecycline are confirmed supportive, especially in
community-acquired pneumonia (CAP), cIAI and compli-
cated skin and skin structure infections (cSSSI) [14], but it
has still not been recommended for the therapy on the
pediatric population, even reports are rare. Among those
rare reports, tigecycline was used to treat meningitis com-
bined with bacteremia caused by vancomycin-resistant
Enterococcus faecium and central venous catheter in-
fection caused by MDR Corynebacter iumjeikeium,
respectively [15,16]. In 2012, Halil Özdemir reported a
nine-year-old girl with acute myeloid leukemia who
was treated successfully with tigecycline due to multidrug-
resistant E. coli bacteremia [17]. Although some researches
have explored for the treatment of infection involved by
KPC-producing Enterobacteriaceae with tigecycline, the
optimal therapy plan is yet to be established for the lack of
the available clinical evidence in children reports.
In this case, we took tigecycline combined with
fosfomycin as treatment option. The recommended
dosage of tigecycline is calculated with 1.2 mg/kg q12h
(no more than 50 mg) in children. During the therapy,
the patient developed vomiting, which it was thought
to be related to fosfomycin at first, and hence fosfomycin
was stopped. But this situation was not completely relieved
until tigecycline was stopped. Therefore, it was very
possible that the vomiting was related to tigecycline. It
has been reported of the side-effect of vomiting involved
by tigecycline that the phase II clinical trials revealed 50%
children suffered from nausea and vomiting, majority of
which were reported as mild to moderate in toxicity of
tigecycline [18,19]. During the usage of tigecycline in our
patient, an E. colace resistant to tigecycline was emerging,
which presents the limitation of tigecycline. There several
researches have reported monotherapy of tigecycline is
restricted for treating infections, which involve with
inducing resistant events and higher mortality [20-22].
Therefore, tigecycline may be used only as salvage
therapy in critically ill patients, and if it is used for
pediatric patients, more concerns should be taken because
of possible side effects.Conclusion
Owing to the limited evidence of tigecycline being used in
pediatric patients, we did some documented experience to
use monotherapy with tigecycline to treat KPC-producing
Enterobacteriaceae infection in children. Our results con-
firmed the effect of tigecycline to control infection caused
be CPE, while drug induced side effects like vomiting and
inducing resistance were also observed during the therapy.
Although infection was controlled successfully in this
case, it is hard to evaluate the efficacy and the safety of
tigecycline in treating pediatric patients, more concerns
should be taken because of possible side effects.
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